A synopsis of the curriculum
• Biopharmaceuticals
• Proteins and polypeptides as therapeutic agents
• Monoclonal antibodies as therapeutic agents
• Basic principles of pharmacogenetics
• Gene delivery
• Controlling gene expression
• Safety issues associated with gene therapy
• Therapeutic areas for gene therapy
Blended distance learning:
Contact Hours: 100 hours
Private Study Time: 50 hours
Total Learning Time: 150 hours
2000 word Essay – 40%
2 hour Examination – 60%
The pass mark for each individual assessment is 40%. All assessments must be passed in order to pass the module.
Humphrey P. Rang, James M. Ritter, Graeme Henderson, Rang, H (2015) Rang & Dale's Pharmacology, 8th edition. Elsevier.
See the library reading list for this module (Medway)
The intended subject specific learning outcomes.
On successfully completing the module students will be able to:
Describe in detail how proteins, polypeptides and monoclonal antibodies can be used as biopharmaceuticals.
Develop an understanding of the basic principles of gene therapy, including gene delivery and expression.
Apply the basic principles of pharmacogenetics.
Develop an in-depth understanding of the methods used to identify genetic variation.
The intended generic learning outcomes.
On successfully completing the module students will be able to:
Develop and demonstrate an ability to analyse, evaluate and correctly interpret data.
Present and communicate data effectively and confidently.
Obtain and use information from a variety of sources as part of self-directed learning.
Manage their time and use their organisation skills within the context of self-directed learning.
Develop and demonstrate an ability to work and communicate effectively with others.
University of Kent makes every effort to ensure that module information is accurate for the relevant academic session and to provide educational services as described. However, courses, services and other matters may be subject to change. Please read our full disclaimer.
